Clinical Trials in Gastroesophageal Cancers: An Analysis of the Global Landscape of Interventional Trials From ClinicalTrials.gov
Although 80% of GECs occur in LMICs, trial activity disproportionately occurs in HICs. Few trials focus on EAC/ESCC despite being highly fatal, highlighting an unmet need. Overall, this study highlights (1) a missed opportunity to recruit patients from high-incidence regions globally; and (2) a pressing need for increasing funding, infrastructure, and support for GEC trials in LMICs.
Authors
- Katherine Van Loon (ORCID: https://orcid.org/0000-0002-9705-4114)
- Ayo Samuel Falade (ORCID: https://orcid.org/0000-0001-9201-6998)
- Oluwatayo Adeoye (ORCID: https://orcid.org/0009-0002-3007-5292)
- Geoffrey Buckle (ORCID: https://orcid.org/0000-0001-7721-0397)
Institutions
- University of California, San Francisco (US)
- Salem Hospital (US)
- St. Elizabeth's Medical Center (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
Publication Details
- Journal
- JCO Global Oncology
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1200/go.24.00169
- Citations
- 2
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.15